Steven Prestrelski, Chief Scientific Officer at XERIS PHARMACEUTICALS INC (XERS), sold 37,662 shares at $17.20 ($453K) on 2019-01-14, disclosed to the SEC on 2019-10-16.
Open-market sale of $453k XERS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.20 | 7,700 | $132K | 29.3% |
| 2 | $12.04 | 9,962 | $120K | 26.5% |
| 3 | $12.04 | 9,962 | $120K | 26.5% |
| 4 | $12.70 | 38 | $483 | 0.1% |
| 5 | $7.97 | 10,000 | $80K | 17.6% |
| Total | $12.01 avg | 37,662 |
| $453K |
| 100% |
| Filing → |
| XERS | SELL | 2021-01-15 | $60K | — | Filing → |
| XERS | SELL | 2021-01-12 | $57K | — | Filing → |
| XERS | SELL | 2020-01-14 | $55K | — | Filing → |